New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
08:07 EDTADXSAdvaxis announces ADXS-HPV publication or preclinical research
Advaxis announced the publication of preclinical research with its lead candidate, ADXS-HPV for the treatment of HPV-associated cancers in the journal, Cancer Immunology Research. In this publication, researchers at the National Cancer Institute reported on the biologic mechanisms behind the unique ability of ADXS-HPV to decrease the immunosuppressive activity of Tregs in the tumor microenvironment that result in increased anti-tumor activity. This research demonstrates the critical role of the tLLO peptide fusion and the strong adjuvant effect of tLLO as contributing to the increase in activated T-cells and the relative decrease in the number of Tregs in tumors, thereby increasing anti-tumor activity. The company said, "The results are better than those achieved in earlier studies with different Lm-based immunotherapies. They suggest that tLLO serves as a promising adjuvant and that its incorporation into ADXS-HPV is a critical contributor to the changes in the tumor microenvironment that favor immune killing of the tumor cells." ADXS-HPV is in clinical trials for three HPV-associated cancers. Advaxis reported final Phase 2 data in recurrent cervical cancer at the 2014 American Society of Clinical Oncology Annual Meeting and plans to move forward with a registration program in recurrent cervical cancer.
News For ADXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
07:38 EDTADXSAdvaxis to receive $1.7M through NJ NOL program
Advaxis announced it has received preliminary approval for a $1.9M tax credit from the New Jersey Technology Business Tax Certificate Transfer, or NOL, Program for the year 2014. The company anticipates that it will be able to transfer this credit and receive approximately $1.7M in cash in mid-December.
November 12, 2014
07:35 EDTADXSAdvaxis submits IND application for ADXS-HPV Phase 1/2 study, MEDI4736
Advaxis (ADXS) announced that the company has submitted an Investigational New Drug application, or IND, to the FDA to conduct a Phase 1/2 study of ADXS-HPV alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. This follows the press release issued in July announcing the clinical trial collaboration between Advaxis and MedImmune, the global biologics research and development arm of AstraZeneca (AZN).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use